Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

RELIEF THERAPEUTICS Holdings AG, CH0100191136

RELIEF THERAPEUTICS Holdings AG, CH0100191136

13.11.2020 - 07:05:26

EQS-News: Relief, with Partner NeuroRx, Announces Enrollment of 150 Patients in Phase 2b/3 Trial of RLF-100 for Critical COVID-19 with Respiratory Failure

NeuroRx, Inc. Jonathan C. Javitt, M.D., MPH Chairman and Chief Executive Officer.ceo@neurorxpharma.com MEDIA CONTACT: Relief (Europe) MC Services AG Anne Hennecke / Brittney Sojevarelief@mc-services.eu +49 (0) 211-529-252-14 NeuroRx (United States) David Schull Russo Partners, LLC david.schull@russopartnersllc.com +1 (0) 858-717-2310 INVESTOR RELATIONS: Relief (Europe) Anne Hennecke / Brittney Sojeva MC Services AG relief@mc-services.eu +49 (0) 211-529-252-14 NeuroRx (United States) Brian Korb Solebury Trout bkorb@troutgroup.com +1 (0) 917-653-5122 ?

?

Additional features:File: Relief, with Partner NeuroRx, Announces Enrollment of 150 Patients in Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure

End of Media Release

Language: English Company: RELIEF THERAPEUTICS Holdings AG Avenue de S?cheron 15 1202 Gen?ve

Switzerland E-mail: contact@relieftherapeutics.com Internet: https://relieftherapeutics.com ISIN: CH0100191136 Listed: SIX Swiss Exchange EQS News ID: 1147913 ? End of News EQS Group News Service

1147913??13.11.2020?

@ dgap.de